Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 25, 2026

I’m 50 years old with $400K in savings, but I’ve heard the magic number for retirement is $1.26 million. Will I be okay?

View original at finance.yahoo.com
I’m 50 years old with $400K in savings, but I’ve heard the magic number for retirement is $1.26 million. Will I be okay? AnnaStills / Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Most Americans are reaching for $1.26M as their magic number for retiring comfortably

    80% confidence
  • Total average expenditures for Americans 65 or over was $61,432 in 2024

    80% confidence
  • Gen Xers have a median 401(k) balance of $217,500

    80% confidence
  • Nearly 50% of Americans are making 1 big Social Security mistake

    80% confidence
  • One asset will surge 400% in a year

    80% confidence
  • Average 401(k) balance among savers aged 50 to 54 was $199,900 as of Q4 2024

    80% confidence
  • Typical retired worker today collects about $2,071 per month in Social Security benefits

    80% confidence
  • Warning issued about what could be coming for U.S. stocks, raising alarm bells for retirees

    80% confidence
  • Social Security fund projected to run out in late 2032, but employer payroll taxes will still fund majority of benefits

    80% confidence
  • Typical 65-year-old could expect to spend $172,500 on health care and medical expenses throughout retirement in 2025

    80% confidence
  • Standard monthly cost for Medicare Part B in 2026 is $202.90

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com